<DOC>
	<DOC>NCT01437059</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-PCS02 in subjects with Elevated LDL-Cholesterol (LDL-C).</brief_summary>
	<brief_title>Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)</brief_title>
	<detailed_description />
	<criteria>Elevated LDLC of &gt;3.0 mmol/L and &lt;5.7 mmol/L Fasting triglyceride concentration â‰¤2.8 mmol/L Body weight &gt;60.0 kg; body mass index (BMI) between 19.00 kg/m2 and &lt;35.00 kg/m2 Adequate blood counts, liver and renal function May not received any lipid lowering drug/agent within the 30 days prior to the screening Nonsmokers for at least 3 months Women of childbearing potential must have a negative pregnancy test, cannot be breast feeding, and must use an adequate method of birth control Males agree to use appropriate contraception Willing and able to comply with protocolrequired visit schedule and visit requirements and provide written informed consent Known hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection Multiple drug allergies or know sensitivity to oligonucleotide History of drug abuse and/or alcohol abuse Receiving an investigational agent within 3 months prior to study drug administration Subjects with safety laboratory test results deemed clinical significant by the Investigator; Received prescription drugs within 4 weeks of first dosing Subjects who have donated more than 500 mL of blood within the 3 months prior to ALNPCS02 or placebo administration; Received megadose vitamin therapy or dietary supplements within 4 weeks prior to screening Subjects who have used prescription drugs within 4 weeks of first dosing Considered unfit for the study by the Principal Investigator Employee or family member of the sponsor or the clinical study site personnel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>